Javier, Cortes, MD, PhD IOB Italy Institute of Oncology Quiron Group Madrid and Barcelona, Spain 5Live #ASCO20
5:10
Key Insights on KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemo vs placebo + chemo for previously untreated locally recurrent inoperable or metastatic TNBC
Breast Cancer
Javier, Cortes, MD, PhD IOB Italy Institute of Oncology Quiron Group Madrid and Barcelona, Spain 5Live #ASCO20
Key Insights on KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemo vs placebo + chemo for previously untreated locally recurrent inoperable or metastatic TNBC
Breast Cancer Similar Videos
Similar Videos
